Cass Edwards1,2,3, Sutapa Mukherjee2, Laila Simpson2,4,5, Lyle J Palmer6, Osvaldo P Almeida7, David R Hillman1,2,3,5. 1. School of Surgery, University of Western Australia, Crawley, Australia. 2. West Australian Sleep Disorders Research Institute, Queen Elizabeth II Medical Centre, Nedlands, Australia. 3. Department of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia. 4. Centre for Genetic Origins of Health and Disease, University of Western Australia, Crawley, Australia. 5. Centre for Sleep Science, School of Anatomy, Physiology and Human Biology, University of Western Australia, Crawley, Australia. 6. The Joanna Briggs Institute and School of Translational Health Science, University of Adelaide, Adelaide, Australia. 7. WA Centre for Health & Ageing and School of Psychiatry & Clinical Neurosciences, University of Western Australia, Crawley, Australia; Department of Psychiatry, Royal Perth Hospital, Perth, Australia.
Abstract
STUDY OBJECTIVES: To determine prevalence of depressive symptoms in obstructive sleep apnea (OSA) and the impact of OSA treatment on depression scores. METHODS: Consecutive new patients referred for investigation of suspected OSA were approached. Consenting patients completed a patient health questionnaire (PHQ-9) for depressive symptoms when attending for laboratory polysomnography. Those with moderate/severe (apneahypopnea index [AHI] ≥ 15 events/h) and/or symptomatic mild OSA (AHI 5-14.99 events/h) were offered continuous positive airway pressure (CPAP) therapy. PHQ-9 was repeated after 3 months of CPAP with compliance recorded. Of a maximum PHQ-9 score of 27, a cut point ≥ 10 (PHQ-9 ≥ 10) was used to indicate presence of clinically significant depressive symptoms. RESULTS: A total of 426 participants (243 males) were recruited. Mean ± standard deviation body mass index (BMI) was 32.1 ± 7.1 kg/m2 and AHI 33.6 ± 28.9 events/h. PHQ-9 was 10.5 ± 6.1 and independently related to AHI (p < 0.001) and BMI (p < 0.001). In those without OSA, PHQ-9 ≥ 10 was more common in women, but no gender difference was evident with OSA. Of 293 patients offered CPAP, 228 were compliant (mean nightly use > 5 h) over 3 months of therapy. In them, with therapy, AHI decreased from 46.7 ± 27.4 to 6.5 ± 1.6 events/h, PHQ-9 from 11.3 ± 6.1 to 3.7 ± 2.9 and PHQ-9 ≥ 10 from 74.6% to 3.9% (p < 0.001 in each case). Magnitude of change in PHQ-9 was similar in men and women. Antidepressant use was constant throughout. CONCLUSIONS: Depressive symptoms are common in OSA and related to its severity. They improve markedly with CPAP, implying a relationship to untreated OSA.
STUDY OBJECTIVES: To determine prevalence of depressive symptoms in obstructive sleep apnea (OSA) and the impact of OSA treatment on depression scores. METHODS: Consecutive new patients referred for investigation of suspected OSA were approached. Consenting patients completed a patient health questionnaire (PHQ-9) for depressive symptoms when attending for laboratory polysomnography. Those with moderate/severe (apneahypopnea index [AHI] ≥ 15 events/h) and/or symptomatic mild OSA (AHI 5-14.99 events/h) were offered continuous positive airway pressure (CPAP) therapy. PHQ-9 was repeated after 3 months of CPAP with compliance recorded. Of a maximum PHQ-9 score of 27, a cut point ≥ 10 (PHQ-9 ≥ 10) was used to indicate presence of clinically significant depressive symptoms. RESULTS: A total of 426 participants (243 males) were recruited. Mean ± standard deviation body mass index (BMI) was 32.1 ± 7.1 kg/m2 and AHI 33.6 ± 28.9 events/h. PHQ-9 was 10.5 ± 6.1 and independently related to AHI (p < 0.001) and BMI (p < 0.001). In those without OSA, PHQ-9 ≥ 10 was more common in women, but no gender difference was evident with OSA. Of 293 patients offered CPAP, 228 were compliant (mean nightly use > 5 h) over 3 months of therapy. In them, with therapy, AHI decreased from 46.7 ± 27.4 to 6.5 ± 1.6 events/h, PHQ-9 from 11.3 ± 6.1 to 3.7 ± 2.9 and PHQ-9 ≥ 10 from 74.6% to 3.9% (p < 0.001 in each case). Magnitude of change in PHQ-9 was similar in men and women. Antidepressant use was constant throughout. CONCLUSIONS:Depressive symptoms are common in OSA and related to its severity. They improve markedly with CPAP, implying a relationship to untreated OSA.
Authors: Devin L Brown; Craig S Anderson; Ronald D Chervin; Clete A Kushida; Daniel S Lewin; Beth A Malow; Susan Redline; Edward B Goldman Journal: J Clin Sleep Med Date: 2011-02-15 Impact factor: 4.062
Authors: Laila Simpson; David R Hillman; Matthew N Cooper; Kim L Ward; Michael Hunter; Stewart Cullen; Alan James; Lyle J Palmer; Sutapa Mukherjee; Peter Eastwood Journal: Sleep Breath Date: 2012-11-16 Impact factor: 2.816
Authors: C Diamanti; E Manali; M Ginieri-Coccossis; K Vougas; K Cholidou; E Markozannes; P Bakakos; I Liappas; M Alchanatis Journal: Sleep Breath Date: 2013-02-06 Impact factor: 2.816
Authors: Colleen L Froese; Arsalan Butt; Alan Mulgrew; Rupi Cheema; Mary-Ann Speirs; Carmen Gosnell; Jon Fleming; John Fleetham; C Frank Ryan; Najib T Ayas Journal: J Clin Sleep Med Date: 2008-08-15 Impact factor: 4.062
Authors: Marcus Povitz; Carmelle E Bolo; Steven J Heitman; Willis H Tsai; JianLi Wang; Matthew T James Journal: PLoS Med Date: 2014-11-25 Impact factor: 11.069
Authors: Matthew D Weaver; Céline Vetter; Shantha M W Rajaratnam; Conor S O'Brien; Salim Qadri; Ruth M Benca; Ann E Rogers; Eileen B Leary; James K Walsh; Charles A Czeisler; Laura K Barger Journal: J Sleep Res Date: 2018-08-01 Impact factor: 3.981
Authors: Obianuju B Ozoh; Oluwadamilola O Ojo; Sandra O Iwuala; Ayesha O Akinkugbe; Olufemi O Desalu; Njideka U Okubadejo Journal: Sleep Breath Date: 2016-09-12 Impact factor: 2.816
Authors: Carol J Lang; Sarah L Appleton; Andrew Vakulin; R Doug McEvoy; Andrew D Vincent; Gary A Wittert; Sean A Martin; Janet F Grant; Anne W Taylor; Nicholas Antic; Peter G Catcheside; Robert J Adams Journal: J Clin Sleep Med Date: 2017-04-15 Impact factor: 4.062
Authors: Harneet K Walia; Sandra D Griffith; Nicolas R Thompson; Douglas E Moul; Nancy Foldvary-Schaefer; Reena Mehra Journal: J Clin Sleep Med Date: 2016-10-15 Impact factor: 4.062